AstraZeneca had some good news for its investors early Monday morning, reporting that their Phase III cardio study offered some compelling proof of their SGLT2 diabetes drug’s ability to reduce the risk of hospitalization for heart failure and CV death. But it was a mixed picture, with Farxiga falling short on a primary endpoint for major reduction in major cardiac events compared to a placebo.
“The results from this landmark trial are especially important since heart failure is an early and frequent complication of diabetes and associated with hospitalisations that result in a considerable societal and economic burden,” noted Elisabeth Björk, vice president and head of cardiovascular for the pharma giant.
AstraZeneca $AZN recruited more than 17,000 patients in 33 countries for this study.
Eli Lilly got out in front of this particular development race when it posted some impressive cardio benefits for patients three years ago. And a year ago Novo Nordisk scored a label expansion to include its own heart benefits for Victoza, giving AstraZeneca a set of major league rivals to contend with on this score.
AstraZeneca plans to detail the numbers at the AHA scientific meeting November 20.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,000+ biopharma pros who read Endpoints News by email every day.Free Subscription